Precision Biosciences (DTIL) Retained Earnings (2018 - 2026)
Precision Biosciences (DTIL) posted quarterly Retained Earnings of -$546.6 million for Q1 2026, down 8.67% year-over-year from -$598.5 million in Q1 2025, and down 3.49% quarter-over-quarter from -$528.2 million in Q4 2025.
Precision Biosciences (DTIL) Retained Earnings (2018 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has reported Retained Earnings for 9 consecutive years, with -$546.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings fell 8.67% year-over-year to -$546.6 million; the TTM figure through Mar 2026 stood at -$546.6 million (down 8.67% YoY), while the FY2025 annual figure was -$528.2 million, down 9.48% from the prior year.
- Retained Earnings slipped to -$546.6 million in Q1 2026 per DTIL's latest filing, from -$528.2 million in the prior quarter.
- Across five years, Retained Earnings topped out at -$344.8 million in Q1 2022 and bottomed at -$548.3 million in Q3 2025.
- Historically, Retained Earnings has averaged -$468.2 million across 5 years, with a median of -$473.3 million in 2023.
- Annual changes were most pronounced in 2022 — Retained Earnings tumbled 35.82% — and 2024, when it climbed 3.65%.
- Precision Biosciences' Retained Earnings stood at -$428.3 million in 2022, then slipped by 14.32% to -$489.6 million in 2023, then gained by 1.46% to -$482.5 million in 2024, then declined by 9.48% to -$528.2 million in 2025, then decreased by 3.49% to -$546.6 million in 2026.
- Business Quant data shows DTIL's Retained Earnings at -$546.6 million in Q1 2026, -$528.2 million in Q4 2025, and -$548.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Precision Biosciences | 228.31 Mn | 140.77 Mn | - | -579.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -579.28 Mn |
| Mar 31, 2026 | -546.63 Mn |
| Dec 31, 2025 | -528.19 Mn |
| Sep 30, 2025 | -548.32 Mn |
| Jun 30, 2025 | -526.55 Mn |
| Mar 31, 2025 | -503.03 Mn |
| Dec 31, 2024 | -482.46 Mn |
| Sep 30, 2024 | -464.72 Mn |
| Jun 30, 2024 | -448.29 Mn |
| Mar 31, 2024 | -481.04 Mn |
| Dec 31, 2023 | -489.63 Mn |
| Sep 30, 2023 | -473.34 Mn |
| Jun 30, 2023 | -465.26 Mn |
| Mar 31, 2023 | -453.37 Mn |
| Dec 31, 2022 | -428.31 Mn |
| Sep 30, 2022 | -399.82 Mn |
| Jun 30, 2022 | -375.88 Mn |
| Mar 31, 2022 | -344.84 Mn |
| Dec 31, 2021 | -316.68 Mn |
| Sep 30, 2021 | -294.39 Mn |